Transanal total mesorectal excision and delayed coloanal anastomosis without stoma for low rectal cancer.
Isaac Seow-EnYvonne Ying-Ru NgIain Beehuat TanEmile John Kwong Wei TanPublished in: Techniques in coloproctology (2022)
The management of low rectal cancer is a perennial challenge for colorectal surgeons. The benefits of transanal total mesorectal excision (TaTME) in low rectal cancer are to secure the distal margin and avoid surgical space constraints within the deep pelvis. However, anastomotic leak remains an important concern. We report our technique and results combining TaTME with delayed coloanal anastomosis (DCAA) without bowel diversion. First, the splenic flexure, left colon and rectum are laparoscopically mobilized to mid-rectum. TaTME is performed to complete the distal rectal mobilization, and the specimen is delivered transanally and transected. The abdominoperineal colonic pull-through is secured to the anal canal and hypertonic dressing is applied regularly in the ward. The handsewn DCAA is performed one week later. An accompanying video demonstrates this technique. Five consecutive patients with low rectal cancer underwent TaTME with DCAA. All had upfront surgical resection except one who underwent total neoadjuvant therapy. Mean operative duration, blood loss, and length of hospital stay was 290 (250-375) min, 142 (10-200) ml and 11.6 (10-14) days respectively. One patient (20%) suffered a postoperative complication of persistent urinary retention, requiring an indwelling urinary catheter on discharge. There were no cases of open conversion and no instances of anastomotic leakage. Two patients (40%) had minor low anterior resection syndrome (LARS) and one (20%) had major LARS. TaTME and DCAA without stoma are complimentary techniques that augment the minimally invasive effects of laparoscopic sphincter-sparing low rectal cancer surgery, with good perioperative outcomes.
Keyphrases
- rectal cancer
- locally advanced
- minimally invasive
- robot assisted
- healthcare
- patients undergoing
- case report
- end stage renal disease
- type diabetes
- randomized controlled trial
- clinical trial
- squamous cell carcinoma
- stem cells
- coronary artery disease
- chronic kidney disease
- prognostic factors
- cardiac surgery
- atrial fibrillation
- bone marrow
- weight loss
- mesenchymal stem cells
- patient reported outcomes
- peripheral blood
- peritoneal dialysis